Gnca stock price today
Get the latest Genocea Biosciences, Inc. (GNCA) stock news and headlines to help you in your trading and investing decisions. Fair Value is the appropriate price for the shares of a company GNCA Price Target and Analyst Ratings (Genocea Biosciences) Oct 29, 2019 · 4 Wall Street analysts have issued ratings and price targets for Genocea Biosciences in the last 12 months. Their average twelve-month price target is $16.33, suggesting that the stock has a possible upside of 883.94%. The high price target for GNCA is $32.00 and the low price target for GNCA is … GNCA | Genocea Biosciences Inc. Analyst Estimates ... Nov 05, 2019 · Genocea Biosciences Inc. analyst estimates by MarketWatch. View GNCA revenue estimates and earnings estimates, as well as analyst recommendations. GNCA | Genocea Biosciences Inc. Stock Price & News - WSJ
GNCA Stock Price | Genocea Biosciences Inc. Stock Quote (U ...
Stock quote for Genocea Biosciences, Inc. Common Stock Common Stock (GNCA) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. GNCA - Genocea Biosciences News - Barchart.com Genocea Biosciences (GNCA) Genocea Biosciences (GNCA) [[ item.lastPrice ]] Today's Price Surprises New Highs & Lows Performance Price Change Funds Screener. Options. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Genocea Biosciences Inc Stock Quote: GNCA Stock News ...
GNCA: Get the latest Genocea Biosciences stock price and detailed information including GNCA news, historical charts and realtime prices.
Get today's Genocea Biosciences Inc stock price and latest GNCA news as well as Genocea Bio real-time stock quotes, technical analysis, full financials and STOCK QUOTE (GNCA). NASDAQ: GNCA. $1.50. Mar 24, 2020 2:42 PM EDT. Change; +0.06 (+4.17%): Volume; 121,137: Today's Open; $1.40: Previous Close View today's stock price, news and analysis for Genocea Biosciences Inc. (GNCA ). Barron's also provides information on historical stock ratings, target prices, A GNCA split history review and split-adjusted CAGR. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. start to finish, an original position size of 1000 shares would have turned into 125 today. Company Name: Genocea Biosciences Inc, Stock Symbol: GNCA, Industry: Last Post: 3/2/2020 7:51:24 PM - Followers: 33 - Board type: Free - Posts Today: 0 Today's Dead Cat Bounce Stock: Genocea Biosciences (GNCA) · By TheStreet Wire. Apr 12, 2016 2:18 PM EDT. New Lifetime High Reached By WGL Holdings
GNCA - Genocea Biosciences News - Barchart.com
Free current stock price quotes and data for Genocea Biosciences Inc (GNCA). Research news, charts, stock market performance and earnings. Quotes Snapshot > GNCA. Genocea Biosciences Inc GNCA:NASDAQ. Set Alert Options Streaming Charts. Last Price $1.66 NASDAQ Closing Price as of 4:00PM ET 4/01/20 NASDAQ 15-minute delayed Bid/Ask Quotes. Today's
Genocea Biosciences, Inc. (GNCA) Company Bio Genocea Biosciences is a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company was founded in 2006 and is based in Cambridge, Massachusetts.
Jan 22, 2020 · Genocea Biosciences, Inc. (NASDAQ:GNCA) is one of the worst performers on the stock market today. At current price of $2.31, the shares have already lost -0.05 points (-2.33% lower) from its previous close of $2.36.
In addition, this page includes various stock data for Genocea Biosciences, such as the latest Genocea Biosciences stock price history, total returns, stock price today in addition to fundamental data such as earnings and dividends as well as valuation measures such as dividend yield and PE ratio. GNCA Genocea Biosciences, Inc. Stock Quote Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor.